1260 related articles for article (PubMed ID: 30286219)
1. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.
Babiuch AS; Han M; Conti FF; Wai K; Silva FQ; Singh RP
JAMA Ophthalmol; 2019 Jan; 137(1):38-46. PubMed ID: 30286219
[TBL] [Abstract][Full Text] [Related]
2. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
3. Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4.
Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; King J; Antoszyk AN; Peters MA; Tolentino M;
JAMA Ophthalmol; 2017 Jun; 135(6):639-649. PubMed ID: 28492860
[TBL] [Abstract][Full Text] [Related]
4. Disorganization of the Retinal Inner Layers as a Predictor of Visual Acuity in Eyes With Macular Edema Secondary to Vein Occlusion.
Mimouni M; Segev O; Dori D; Geffen N; Flores V; Segal O
Am J Ophthalmol; 2017 Oct; 182():160-167. PubMed ID: 28837790
[TBL] [Abstract][Full Text] [Related]
5. SCORE2 Report 2: Study Design and Baseline Characteristics.
Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Figueroa M; Dugel PU;
Ophthalmology; 2017 Feb; 124(2):245-256. PubMed ID: 27863843
[TBL] [Abstract][Full Text] [Related]
6. Effects of Switching to Aflibercept in Treatment Resistant Macular Edema Secondary to Retinal Vein Occlusion.
Spooner K; Fraser-Bell S; Hong T; Chang A
Asia Pac J Ophthalmol (Phila); 2020; 9(1):48-53. PubMed ID: 31990746
[TBL] [Abstract][Full Text] [Related]
7. Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice.
Wai KM; Khan M; Srivastava S; Rachitskaya A; Silva FQ; Deasy R; Schachat AP; Babiuch A; Ehlers JP; Kaiser PK; Yuan A; Singh RP
Br J Ophthalmol; 2017 May; 101(5):574-579. PubMed ID: 27503394
[TBL] [Abstract][Full Text] [Related]
8. Disorganization of the Retinal Inner Layers after Anti-VEGF Treatment for Macular Edema due to Branch Retinal Vein Occlusion.
Nakano E; Ota T; Jingami Y; Nakata I; Hayashi H; Yamashiro K
Ophthalmologica; 2018; 240(4):229-234. PubMed ID: 30089307
[TBL] [Abstract][Full Text] [Related]
9. Month 24 Outcomes After Treatment Initiation With Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial.
Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA; Chan CK;
JAMA Ophthalmol; 2019 Dec; 137(12):1389-1398. PubMed ID: 31600368
[TBL] [Abstract][Full Text] [Related]
10. Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion.
Cohen MN; Houston SK; Juhn A; Ho AC; Regillo CD; Vander J; Chiang A
Can J Ophthalmol; 2016 Oct; 51(5):342-347. PubMed ID: 27769324
[TBL] [Abstract][Full Text] [Related]
11. Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA;
JAMA Ophthalmol; 2022 May; 140(5):458-464. PubMed ID: 35323843
[TBL] [Abstract][Full Text] [Related]
12. Spectral Domain OCT Predictors of Visual Acuity in the Study of COmparative Treatments for REtinal Vein Occlusion 2: SCORE 2 Report 15.
Etheridge T; Blodi B; Oden N; Van Veldhuisen P; Scott IU; Ip MS; Mititelu M; Domalpally A
Ophthalmol Retina; 2021 Oct; 5(10):991-998. PubMed ID: 33373715
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
[TBL] [Abstract][Full Text] [Related]
14. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Shalchi Z; Mahroo O; Bunce C; Mitry D
Cochrane Database Syst Rev; 2020 Jul; 7(7):CD009510. PubMed ID: 32633861
[TBL] [Abstract][Full Text] [Related]
15. Disorganization of Retinal Inner Layers and Ellipsoid Zone Disruption Predict Visual Outcomes in Central Retinal Vein Occlusion.
Chan EW; Eldeeb M; Sun V; Thomas D; Omar A; Kapusta MA; Galic IJ; Chen JC
Ophthalmol Retina; 2019 Jan; 3(1):83-92. PubMed ID: 30929820
[TBL] [Abstract][Full Text] [Related]
16. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.
Scott IU; VanVeldhuisen PC; Ip MS; Blodi BA; Oden NL; Awh CC; Kunimoto DY; Marcus DM; Wroblewski JJ; King J;
JAMA; 2017 May; 317(20):2072-2087. PubMed ID: 28492910
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study: Bevacizumab for RVO long-term follow-up).
Kornhauser T; Schwartz R; Goldstein M; Neudorfer M; Loewenstein A; Barak A
Graefes Arch Clin Exp Ophthalmol; 2016 May; 254(5):835-44. PubMed ID: 26269374
[TBL] [Abstract][Full Text] [Related]
18. Real-World Outcomes of Ranibizumab Treatment in French Patients with Visual Impairment due to Macular Edema Secondary to Retinal Vein Occlusion: 24-Month Results from the BOREAL-RVO Study.
Glacet-Bernard A; Girmens JF; Kodjikian L; Delcourt C; Fajnkuchen F; Creuzot-Garcher C; San Nicolas N; Massin P
Ophthalmic Res; 2023; 66(1):824-834. PubMed ID: 36972579
[TBL] [Abstract][Full Text] [Related]
19. Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
Wells JA; Glassman AR; Jampol LM; Aiello LP; Antoszyk AN; Baker CW; Bressler NM; Browning DJ; Connor CG; Elman MJ; Ferris FL; Friedman SM; Melia M; Pieramici DJ; Sun JK; Beck RW;
JAMA Ophthalmol; 2016 Feb; 134(2):127-34. PubMed ID: 26605836
[TBL] [Abstract][Full Text] [Related]
20. Predictors of As-Needed Ranibizumab Injection Frequency in Patients With Macular Edema Following Retinal Vein Occlusion.
Yiu G; Huang D; Wang Y; Wang Z; Yang M; Haskova Z
Am J Ophthalmol; 2023 May; 249():74-81. PubMed ID: 36646240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
